A number of research firms have changed their ratings and price targets for DexCom (NASDAQ: DXCM):

  • 1/16/2018 – DexCom had its “sell” rating reaffirmed by analysts at Northland Securities. They now have a $40.00 price target on the stock.
  • 1/8/2018 – DexCom had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $60.00 price target on the stock.
  • 1/4/2018 – DexCom was downgraded by analysts at Northland Securities from a “market perform” rating to an “under perform” rating. They now have a $85.00 price target on the stock.
  • 1/4/2018 – DexCom was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 12/22/2017 – DexCom was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 12/22/2017 – DexCom had its price target raised by analysts at Jefferies Group LLC from $58.00 to $70.00. They now have a “buy” rating on the stock.
  • 12/12/2017 – DexCom had its price target raised by analysts at BMO Capital Markets to $74.00. They now have an “outperform” rating on the stock.
  • 12/12/2017 – DexCom was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.

DexCom, Inc. (NASDAQ DXCM) opened at $56.41 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. The firm has a market capitalization of $4,900.00, a PE ratio of -98.96 and a beta of 0.31. DexCom, Inc. has a twelve month low of $42.62 and a twelve month high of $86.74.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%. equities analysts predict that DexCom, Inc. will post -0.64 EPS for the current year.

In other news, Director Steven R. Altman purchased 10,000 shares of the company’s stock in a transaction on Monday, November 6th. The shares were purchased at an average price of $49.61 per share, with a total value of $496,100.00. Following the purchase, the director now directly owns 4,353 shares of the company’s stock, valued at approximately $215,952.33. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Andrew K. Balo sold 6,490 shares of DexCom stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total value of $389,400.00. The disclosure for this sale can be found here. Insiders sold a total of 38,140 shares of company stock worth $2,158,576 in the last three months. Company insiders own 1.70% of the company’s stock.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with MarketBeat.com's FREE daily email newsletter.